InvestorsHub Logo
Followers 15
Posts 2477
Boards Moderated 0
Alias Born 03/09/2017

Re: Work Harder post# 75419

Sunday, 08/06/2017 3:52:41 PM

Sunday, August 06, 2017 3:52:41 PM

Post# of 106839
Nice post. Here is a link regarding J&J dumping Capricor stem cell drug:

http://www.biopharmadive.com/news/jj-drops-stem-cell-partner-capricor/446688/

This is particularly interesting: Capricor is changing the indication for their drug (stem cells).

"...Capricor is now pursuing CAP-1002 as a treatment for Duchenne muscular dystrophy."

Why did they give up on treating CHF?

Meanwhile, I believe Mesoblast is still looking for a new partner to help fund their 100 million dollar trials.

Of the three: USRM, Mesoblast, and Capricor, who had the best results from their trails for treating CHF?

What does this say about USRM's competition?

Could J&J be looking at USRM?

My one post for the day..:)